We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)

This study is currently recruiting participants.
Verified August 2017 by DNAtrix, Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02798406
First Posted: June 14, 2016
Last Update Posted: August 30, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
DNAtrix, Inc.
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2020
  Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)